



Advances in Supportive Care in Cancer during Pandemics and Natural Disasters: COVID-19 and Beyond

Guest Editor:

Dr. Raffaele Giusti

Medical Oncology Unit,
Sant'Andrea Hospital of Rome,
Rome, Italy

Deadline for manuscript
submissions:

closed (31 October 2021)

Message from the Guest Editor

Natural disasters are becoming more frequent and severe, placing additional strains on supportive care services among cancer patients. Although supportive and palliative care are considered essential components of disaster planning and response, there are gaps in understandings about their real-life applications.

Cancer care has been profoundly impacted by the global pandemic of severe acute respiratory syndrome coronavirus 2 disease (coronavirus disease 2019 (COVID-19)), resulting in unprecedented challenges. Both supportive and palliative care are essential components of cancer treatment, which seek to prevent and manage chemotherapy complications, such as febrile neutropenia, anaemia, thrombocytopenia/bleeding, thromboembolic events and nausea/vomiting, all of which are common causes of hospitalisation. These adverse events are an essential consideration under routine patient management, but particularly so during a pandemic—a setting in which clinicians aim to minimise patients' risk of infection and need for hospital visits.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com